

Birte Yding Glenthøj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8644273/publications.pdf>

Version: 2024-02-01

95
papers

3,543
citations

147801

31
h-index

155660

55
g-index

97
all docs

97
docs citations

97
times ranked

5673
citing authors

#	ARTICLE	IF	CITATIONS
1	The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. <i>Psychological Medicine</i> , 2023, 53, 1266-1276.	4.5	8
2	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 102-107.	1.3	2
3	Dopaminergic Activity in Antipsychotic-Na ⁺ ve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. <i>Biological Psychiatry</i> , 2022, 91, 236-245.	1.3	14
4	Differential effects of age at illness onset on verbal memory functions in antipsychotic-na ⁺ ve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021, 51, 1570-1580.	4.5	17
5	Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Na ⁺ ve Patients With Schizophrenia or Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 278-287.	1.3	36
6	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. <i>Brain and Behavior</i> , 2021, 11, e01962.	2.2	10
7	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-na ⁺ ve adult ADHD patients. <i>European Neuropsychopharmacology</i> , 2021, 46, 83-92.	0.7	4
8	The relation between dopamine D ₂ receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2020, 50, 220-228.	4.5	22
9	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 190.	11.0	23
10	Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 649-655.	5.4	6
11	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies. <i>Schizophrenia Research</i> , 2020, 215, 38-48.	2.0	36
12	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 569-579.	1.5	12
13	M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NA ⁺ VE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT. <i>Schizophrenia Bulletin</i> , 2020, 46, S190-S190.	4.3	0
14	M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NA ⁺ VE SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , 2020, 46, S191-S192.	4.3	0
15	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. <i>European Psychiatry</i> , 2020, 63, e83.	0.2	7
16	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , 2020, 294, 113498.	3.3	3
17	Associations of neural processing of reward with posttraumatic stress disorder and secondary psychotic symptoms in trauma-affected refugees. <i>HÅrgre Utbildning</i> , 2020, 11, 1730091.	3.0	9
18	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. <i>Psychiatry Research</i> , 2020, 290, 112969.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Startle habituation, sensory, and sensorimotor gating in trauma-affected refugees with posttraumatic stress disorder. <i>Psychological Medicine</i> , 2019, 49, 581-589.	4.5	14
20	Validation of the Danish version of the brief negative symptom scale. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 425-432.	1.3	16
21	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019, 5, 12.	3.6	28
22	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60
23	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	4.8	52
24	17.3 USING RASCH ANALYSIS TO IDENTIFY NEGATIVE SYMPTOM RESPONSE TRAJECTORIES IN FIRST-EPISODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S116-S116.	4.3	0
25	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. <i>Psychological Medicine</i> , 2019, 49, 2617-2625.	4.5	8
26	Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study. <i>Neuropsychopharmacology</i> , 2019, 44, 581-589.	5.4	28
27	Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients. <i>Psychoneuroendocrinology</i> , 2018, 92, 72-80.	2.7	26
28	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence – A Danish nationwide study. <i>Schizophrenia Research</i> , 2018, 199, 116-122.	2.0	10
29	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , 2018, 48, 604-616.	4.5	14
30	Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. <i>Biological Psychiatry</i> , 2018, 83, 492-498.	1.3	374
31	Negative Symptoms and Reward Disturbances in Schizophrenia Before and After Antipsychotic Monotherapy. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 36-45.	1.7	24
32	White matter maturation during 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 65-78.	4.5	23
33	O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S80-S80.	4.3	0
34	Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2018, 9, 22.	2.6	24
35	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 1332-1340.	4.3	20
36	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	7.4	141

#	ARTICLE	IF	CITATIONS
37	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 997-1006.	2.1	11
38	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	2.4	61
39	No cognitive-enhancing effect of <sc>GLP</sc>-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 52-62.	4.5	36
40	Two subgroups of antipsychotic-naïve, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , 2017, 7, e1087-e1087.	4.8	32
41	Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register. <i>EBioMedicine</i> , 2017, 18, 320-326.	6.1	22
42	Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. <i>Psychological Medicine</i> , 2017, 47, 2689-2707.	4.5	32
43	Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy. <i>Psychological Medicine</i> , 2017, 47, 2155-2165.	4.5	16
44	Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. <i>Psychological Medicine</i> , 2017, 47, 377-388.	4.5	30
45	“No cognitive-enhancing effect of <sc>GLP</sc>-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia”: authors' response. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 526-527.	4.5	0
46	Auditory processing in autism spectrum disorder: Mismatch negativity deficits. <i>Autism Research</i> , 2017, 10, 1857-1865.	3.8	49
47	Testing a decades-old assumption: Are individuals with lower sensory gating indeed more easily distracted?. <i>Psychiatry Research</i> , 2017, 255, 387-393.	3.3	9
48	Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 539-549.	2.6	4
49	Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?. <i>European Neuropsychopharmacology</i> , 2016, 26, 1248-1250.	0.7	25
50	Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv109.	2.1	18
51	Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: A case control study. <i>Psychiatry Research</i> , 2016, 241, 201-206.	3.3	20
52	Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. <i>Psychiatry Research</i> , 2016, 240, 163-169.	3.3	33
53	Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. <i>BMC Psychiatry</i> , 2016, 16, 348.	2.6	16
54	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. <i>JAMA Psychiatry</i> , 2016, 73, 121.	11.0	68

#	ARTICLE	IF	CITATIONS
55	Frontal fasciculi and psychotic symptoms in antipsychotic-naïve patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 133-141.	2.4	44
56	Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory. <i>Autism Research</i> , 2015, 8, 371-378.	3.8	29
57	Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports. <i>Travel Medicine and Infectious Disease</i> , 2015, 13, 80-88.	3.0	35
58	Striatal D _{2/3} Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. <i>Schizophrenia Bulletin</i> , 2015, 41, 1143-1152.	4.3	34
59	Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. <i>Schizophrenia Bulletin</i> , 2015, 41, 574-583.	4.3	94
60	Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. <i>Schizophrenia Bulletin</i> , 2015, 41, 584-596.	4.3	36
61	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Schizophrenia Bulletin</i> , 2015, 41, 549-558.	4.3	47
62	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 142-170.	2.6	106
63	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. <i>Schizophrenia Bulletin</i> , 2015, 41, 559-573.	4.3	93
64	Neocortical serotonin _{2A} receptor binding predicts quetiapine associated weight gain in antipsychotic-naïve first-episode schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1729-1736.	2.1	22
65	Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome. <i>European Journal of Human Genetics</i> , 2014, 22, 1283-1289.	2.8	69
66	Structural brain correlates of sensorimotor gating in antipsychotic-naïve men with first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 34-42.	2.4	29
67	Norquetiapine and Depressive Symptoms in Initially Antipsychotic-Naïve First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 266-269.	1.4	7
68	Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients. <i>Biological Psychiatry</i> , 2012, 71, 898-905.	1.3	197
69	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012, 10, 92.	5.5	24
70	A Gene Co-Expression Network in Whole Blood of Schizophrenia Patients Is Independent of Antipsychotic-Use and Enriched for Brain-Expressed Genes. <i>PLoS ONE</i> , 2012, 7, e39498.	2.5	125
71	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , 2011, 20, 4076-4081.	2.9	193
72	Serotonin 2A receptor antagonists for treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1211-1223.	4.1	72

#	ARTICLE	IF	CITATIONS
73	Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 69-82.	2.1	78
74	Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 95-104.	2.4	103
75	Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia—Gating of auditory-evoked potentials and prepulse inhibition. <i>Behavioural Brain Research</i> , 2010, 213, 142-147.	2.2	23
76	Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting. <i>Psychopharmacology</i> , 2009, 206, 631-640.	3.1	54
77	Effect of an NCAM mimetic peptide FGL on impairment in spatial learning and memory after neonatal phencyclidine treatment in rats. <i>Behavioural Brain Research</i> , 2009, 199, 288-297.	2.2	29
78	Evaluation of a neurodevelopmental model of schizophrenia—Early postnatal PCP treatment in attentional set-shifting. <i>Behavioural Brain Research</i> , 2008, 190, 160-163.	2.2	66
79	Decreased gene expression of neuropeptide Y and its receptors in hippocampal regions during ethanol withdrawal in rats. <i>Neuroscience Letters</i> , 2007, 424, 160-164.	2.1	14
80	Prepulse inhibition in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 1045-1050.	3.1	50
81	Gating of the vertex somatosensory and auditory evoked potential P50 and the correlation to skin conductance orienting response in healthy men. <i>Psychiatry Research</i> , 2001, 101, 221-235.	3.3	51
82	A mixed modality paradigm for recording somatosensory and auditory P50 gating. <i>Psychiatry Research</i> , 2001, 105, 79-86.	3.3	14
83	Information Processing and Attentional Dysfunctions as Vulnerability Indicators in Schizophrenia Spectrum Disorders. <i>World Journal of Biological Psychiatry</i> , 2000, 1, 5-15.	2.6	21
84	Proprioceptive evoked potentials in man: cerebral responses to changing weight loads on the hand. <i>Neuroscience Letters</i> , 2000, 288, 111-114.	2.1	10
85	Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1997, 21, 23-46.	4.8	57
86	Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function. <i>Psychopharmacology</i> , 1993, 113, 157-166.	3.1	21
87	Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. <i>Brain Research</i> , 1993, 619, 39-54.	2.2	33
88	Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756). <i>European Journal of Pharmacology</i> , 1993, 242, 283-291.	3.5	5
89	Electrical kindling of rats treated discontinuously or continuously with haloperidol. <i>European Journal of Pharmacology</i> , 1993, 236, 401-409.	3.5	7
90	Development of vacuous chewing movements in rats: Role of housing environment. <i>Life Sciences</i> , 1991, 48, 2137-2140.	4.3	12

#	ARTICLE	IF	CITATIONS
91	Intermittent versus continuous neuroleptic treatment in a rat model. European Journal of Pharmacology, 1990, 190, 275-286.	3.5	34
92	Effect of a dopamine D-1 agonist in rats treated chronically with zuclopenthixol. Life Sciences, 1990, 47, 1339-1346.	4.3	7
93	Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. European Journal of Pharmacology, 1989, 164, 393-396.	3.5	30
94	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. Schizophrenia Bulletin Open, 0, , .	1.7	2
95	The relationship between grey matter volume and clinical and functional outcomes in people at clinical high risk for psychosis. Schizophrenia Bulletin Open, 0, , .	1.7	0